Should Peptide Scientists Ignore the Peptide Craze? 

By Judy Myers 

October 14, 2026 | Unregulated injectable peptides promising better aging, better healing, and better sex are being consumed by a growing number of people, says Harvard Health Publishing. The Guardian and Scientific American are calling the phenomenon a “craze,” while JAMA reported that peptide-related hashtags exceeded 230 million TikTok views as of May 2026.  With such massive public engagement, is the peptide craze too big for peptide scientists to ignore? 

Peptide users purchase off-brand compounds labeled “For Research Only” or “Not for Human Use” directly from factories in China or websites of American intermediaries, according to the New York Times. The peptides are not approved by the FDA, constituting a gray market, says CBS Albany.  

Many gray market peptides pose serious health risks. Australia’s poisons hotline received more calls related to unapproved peptides the first six months of 2026 than in the two previous years combined, according to Australian Financial Review.  An April 2026 preprint from the US-based Performance Medicine Institute evaluated the purity of gray market peptides and found that up to 71.1% of 6,441 samples failed to meet basic quality criteria for FDA regulatory standards. 

Federal regulators on both sides of the pond are responding. In the EU, the European Medicines Agency tightened regulations concerning the manufacture and analytical control for synthetic peptides, per Pharmaceutical Online. In Australia, the Therapeutic Goods Administration made unapproved peptides a priority focus area for compliance, unlawful importation, supply, and advertising.  

But regulatory actions have not been uniform.  In the US, the FDA’s Pharmacy Compounding Advisory Committee voted against the advice of FDA scientists to recommend that six out of seven peptides be added to a list that would allow compounding pharmacies to distribute them. Many members of the committee have ties to the peptide industry, according to Time magazine. None of the six peptides currently have FDA approval, making regulations murky, says international law firm Buchanan Ingersoll & Rooney. 

The Safety Risks of a Gray Market 

This tangled web of gray market boom and regulatory ambiguity has already affected peptide researchers and pharmaceutical manufacturers in the US. 

Recently, collaborators from Stanford University and University of California, Berkeley  identified an obesity-related peptide. Their research was published in Nature, and lead author Katrin Svensson co-founded a company to launch clinical trials, according to Drug Discovery World. Much to her surprise, Svensson found her peptide selling on the gray market, according to Stanford Medicine News Center. 

Novo Nordisk launched a Prevent, Detect, and Respond campaign to counteract illicit compounding of semaglutide, the active ingredient in Ozempic and Wegovy.  Eli Lilly filed six lawsuits against US-based spas, wellness clinics, and suppliers for marketing illegal versions of retatrutide—still in late-phase clinical trials—for human consumption, according to Pharmaceutical Commerce.  

Within the academic research community, peptide engineer Dirk Linke, PhD, believes the media can play a part in curtailing or eliminating the gray market. Linke, a professor of Molecular Microbiology at the University of Oslo, has identified a synthetic peptide that can facilitate the detection and removal of bacterial endotoxins from patients’ blood. “Bacterial endotoxins are one of the key causes of sepsis or blood poisoning, which can be fatal,” he says. 

Bacterial endoctoxin contamination was present in 15% of 6,441 samples of gray market peptides tested in a 2026  preprint. Linke says that makes it “suicidal” to buy them off the internet. He believes that calling the marketplace “gray” underplays the dangers of unregulated peptides and implies a legitimacy it does not deserve. “These things have not been approved by the FDA, so it is not legal to sell them as medicines. That’s not a gray market. That’s a black market, and the media should refer to it as such,” says Linke. The distinction is important. According to law firm Mayer/Brown, gray-market goods are authentic, non-counterfeit products, while black markets involve unsafe or counterfeit products, according to US Legal. 

Ironically, there may be a positive aspect to this craze. Dr. Maria Jose Alonso is a pioneer in the field of nanomedicine and is on the Medicine Maker’s Power List of the most influential researchers in the field of Biopharmaceuticals for 2020 and 2021.  She believes that the current greater acceptance of injectables is paving the way for second-generation formulations, adding, “There is also a renovated interest in oral peptide delivery, coming from the fact that semaglutide is now being administered orally. That’s really opened up the field.” 

Both researchers will present next month at PEGS Europe in Lisbon. Jose Alonso will deliver a presentation titled “From Oral/Nasal Delivery to Intracellular Targeting: New Frontiers in Peptide-Based Nanomedicine.”  Linke will elucidate his new peptide in his talk “A New Technology for Endotoxin Removal from Biologicals and from Patient Blood.”